PCA
EXAS

Pallas Capital Advisors’s Exact Sciences EXAS Stock Holding History

Pallas Capital Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,034
Closed -$2.03M – 900
2025
Q4 		$2.03M Buy
20,034
+12,941
+182% +$1.04M 0.07% 214
2025
Q3 		$388K Sell
7,093
-6,341
-47% -$317K 0.01% 597
2025
Q2 		$714K Buy
13,434
+4,925
+58% +$250K 0.03% 409
2025
Q1 		$368K Buy
+8,509
New +$431K 0.02% 548

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Pallas Capital Advisors's EXAS Position: Q1 2026 in Review

Pallas Capital Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 20,034 shares — an estimated $2.03M sold.

Pallas Capital Advisors first reported a position in EXAS in Q1 2025 and held it in 4 quarters. The position peaked at $2.03M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Pallas Capital Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Pallas Capital Advisors sold 20,034 Exact Sciences shares in Q1 2026, an estimated $2.03M.
  • Pallas Capital Advisors first reported a position in Exact Sciences in Q1 2025 and held it in 4 quarters.
  • Pallas Capital Advisors's Exact Sciences position peaked at $2.03M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.